Compare IMCR & AVAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | AVAH |
|---|---|---|
| Founded | 2008 | 1984 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 2016 | 2021 |
| Metric | IMCR | AVAH |
|---|---|---|
| Price | $31.49 | $14.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $66.33 | $9.75 |
| AVG Volume (30 Days) | 356.7K | ★ 3.2M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.39 | ★ 1850.00 |
| EPS | 0.23 | ★ 0.37 |
| Revenue | $249,428,000.00 | ★ $2,433,199,000.00 |
| Revenue This Year | $14.57 | $7.31 |
| Revenue Next Year | $8.21 | $5.59 |
| P/E Ratio | $138.15 | ★ $38.68 |
| Revenue Growth | ★ 43.05 | 20.19 |
| 52 Week Low | $27.56 | $5.93 |
| 52 Week High | $40.71 | $14.54 |
| Indicator | IMCR | AVAH |
|---|---|---|
| Relative Strength Index (RSI) | 30.70 | 74.69 |
| Support Level | $30.47 | $6.22 |
| Resistance Level | $33.55 | N/A |
| Average True Range (ATR) | 1.11 | 0.50 |
| MACD | -0.68 | -0.05 |
| Stochastic Oscillator | 9.06 | 77.68 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.